Bicalutamide is an androgen receptor inhibitor used to treat Stage D2 metastatic carcinoma of the prostate. Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer.
- Mechanism
- Curator reviewed
Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
- Primary indication
- Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.Curator reviewed · 1 structured indication
- Formula / weight
- C18H14F4N2O4S · 430.373 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1995
- Code names
- ICI-176334 · ICI176,334-1
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
LKJPYSCBVHEWIU-UHFFFAOYSA-NSMILESCC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)FTargets
Transporters
What you can answer from here — as of September 12, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Bicalutamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account